Single-tablet HIV treatment shows better outcomes over multi-tablet regimen | RSS News Feed

Single-tablet HIV treatment shows better outcomes over multi-tablet regimen - Latest News

RSS Feed for this news: Single-tablet HIV treatment shows better outcomes over multi-tablet regimen

Single-tablet HIV treatment shows better outcomes over multi-tablet regimen

Taking one tablet per day, versus multiple tablets, appears to result in better outcomes for HIV patients. Credit: Mitch Mirkin HIV patients on a single-tablet daily regimen had better treatment retention and viral suppression than patients taking multiple ... read more

New Insights into HIV Treatment

Single-table HIV treatment was found to show better outcomes over multi-tablet regimen ... They looked at 622 patients on a single-tablet regimen and 406 on a multi-tablet regimen, all taken once daily. While both regimens were based around the drug ... read more

Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA® Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients

Search Skip to Navigation Skip to Market Summary Skip to Main Content Skip to Related Content Sign in read more

Looking for another news?


Medicaid policy may deny access to HIV medication

The U.S. Department of Health and Human Services raised concerns about the safety of Atripla over ... single-tablet regimens are where HIV treatment is headed, and having these regimens instead of patients taking eight to 10 pills a day is much better ... read more

Gilead Sciences' (GILD) Management Presents at Cowen & Company 35th Annual Health Care Conference (Transcript)

These single-tablet regimens are proven to be very popular with patients and they really do help to increase adherence and therefore better patient outcomes ... in HIV-HCV co-infected patients with genotype 1 or genotype 4 and we showed that over 96% ... read more

Gilead Sciences' CEO Presents at The 30th Annual JPMorgan Chase Healthcare Conference (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD) The 30th Annual JPMorgan Chase Healthcare Conference ... the treatment of HIV. We partnered with Bristol-Myers and Merck with their efavirenz to combine it with Truvada to have a single-tablet regimen, ATRIPLA, and ... read more

Gilead Sciences' Management Presents at the 2013 UBS Global Healthcare Conference (Transcript)

We currently have over – we have 15 marketed products. We're primarily known for our HIV franchise which you see there to the right of your slide, multiple single tablet regimens ... for both treatment naïve as well as no responders. The outcome of ... read more

Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA® Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients

Once-daily single tablet complete regimen demonstrates effective viral suppression ... the efficacy and safety of D/C/F/TAF versus the control in HIV-1 positive treatment-naïve adult patients over 48 weeks. The control comprised two separate medications ... read more


FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us